Global Insulin Delivery Devices Market to Grow at 7.1% CAGR by 2031, Driven by Smart Pens, Automated Insulin Pumps, and Digital Health Integration

Insulin Delivery devices Market is growing at a CAGR of 7.1% in the forecast period 2024-2031.

The Insulin Delivery Devices Market includes pens, pumps, syringes, and jet injectors used for administering insulin to diabetic patients. Market growth is driven by the global increase in diabetes prevalence and the demand for convenient, pain-free delivery systems. Technological innovations in smart insulin pens and closed-loop pumps enhance precision and user experience. Manufacturers focus on digital integration for glucose monitoring and data connectivity. Rising awareness about diabetes management and patient comfort further fuel adoption. The market outlook remains strong with growing emphasis on personalized and automated insulin therapy.

📌 Download Sample Report to Identify Emerging Deals & Opportunities in the Insulin Delivery devices Market Landscape:- https://datamintelligence.com/download-sample/insulin-delivery-devices-market?rk

☛ Automated Insulin Delivery (AID) Systems / Hybrid Closed-Loop Systems
This is the most advanced category. These systems connect a Continuous Glucose Monitor (CGM) to an insulin pump, which automatically adjusts insulin delivery based on real-time glucose levels.

Tandem t:slim X2 with Control-IQ Technology: A leader in the space. Its algorithm predicts high and low glucose levels and automatically adjusts insulin. It includes features like an Exercise Mode for better management during physical activity.

Medtronic MiniMed 780G: This system features a SmartGuard algorithm that automatically corrects high blood sugar and suspends insulin delivery when glucose is predicted to go low. A key feature is its auto-correction bolus, which delivers small automatic doses to correct highs.

Insulet Omnipod 5: The first tubeless AID system. The Pod communicates directly with a compatible smartphone and Dexcom G6 CGM to automatically adjust insulin delivery. It is fully waterproof and controlled via a dedicated device or a compatible phone.

☛ Next-Generation Smart Insulin Pens
Smart pens bridge the gap between the simplicity of injections and the technology of pumps. They record doses and timing, providing valuable data for better management.

Novo Nordisk's Smart Pens: The NovoPen 6 and NovoPen Echo Plus connect via Bluetooth to apps to log insulin dose data (dose size, time, and type), helping to solve the problem of forgotten doses.

Companion Medical's InPen: (Now part of Medtronic) This smart reusable pen calculates bolus doses, tracks insulin on board, and sends data directly to a smartphone app. It can integrate with CGM data for more informed dosing decisions.

☛ Innovations in Insulin Pumps
Beyond AID, pumps themselves are becoming more discrete and user-friendly.

Tandem's Mobi: This is a new, miniaturized hybrid closed-loop system. It is significantly smaller than traditional pumps and can be worn directly on the body or carried in a pocket. It is fully controlled by a smartphone app.

Insulet Omnipod GO: A new, simpler Pod designed specifically for people with Type 2 diabetes on multiple daily injections. It delivers a preset basal rate of insulin for up to three days, simplifying one part of their regimen.

Medtronic MiniMed 780G/770G: These systems offer advanced automation and were among the first with integrated Bluetooth connectivity for direct data upload to the cloud for remote monitoring.

☛ Key Trends and Future Innovations
Full Smartphone Control: The industry is moving toward using a patient's own smartphone as the primary controller for pumps and smart pens, reducing the need to carry separate devices.

Integrated Digital Ecosystems: Data from CGMs, smart pens, and pumps is being unified in apps and cloud platforms to provide a holistic view for both the user and their healthcare team.

Dual-Hormone Pumps (Future): Research is ongoing into pumps that can deliver both insulin (to lower glucose) and glucagon (to raise it), creating a truly "fully closed-loop" system.

Patch Pumps and Miniaturization: The trend is toward smaller, tubeless "patch pumps" that are more discrete and comfortable to wear.

☛ Insulin Delivery devices Market Competitve Landscape:

Novo Nordisk, GlaxoSmithKline, Bristol-Myers Squibb, Becton Dickinson, Eli Lilly and Company, Merck & Co., AstraZeneca, Sanofi, Roche Holding AG, Amgen, Johnson & Johnson, Abbott Laboratories and Tandem diabetes care.

Research Methodology

We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.

📌 Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/insulin-delivery-devices-market

☛ Segment Covered in the Insulin Delivery devices Market:

By Product Type: Syringes, Insulin Pens, and dosers, Infusion pumps, Oral insulin, Insulin sprays, Insulin patches, Jet injectors, Automated insulin delivery system.

By Application: Type I Diabetes, Type II Diabetes.

By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Sales and Others.

☛ This Report Includes:

✔ Comprehensive go-to-market strategies with actionable insights.

✔ Unbiased evaluation of overall market performance.

✔ Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.

✔ Tailored regional and country-level reports with detailed localized analysis available on request.

✔ Identification of niche segments and high-growth regions presenting strong opportunities.

✔ Accurate regional forecasts using both top-down and bottom-up approaches.

📌 Get Corporate Access to Live Insulin Delivery devices Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=insulin-delivery-devices-market

☛ Regional Analysis for Insulin Delivery devices Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.